Erik Asmus

686 total citations
9 papers, 179 citations indexed

About

Erik Asmus is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Erik Asmus has authored 9 papers receiving a total of 179 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 4 papers in Pulmonary and Respiratory Medicine and 3 papers in Cancer Research. Recurrent topics in Erik Asmus's work include Advanced Breast Cancer Therapies (4 papers), Multiple Myeloma Research and Treatments (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). Erik Asmus is often cited by papers focused on Advanced Breast Cancer Therapies (4 papers), Multiple Myeloma Research and Treatments (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). Erik Asmus collaborates with scholars based in United States. Erik Asmus's co-authors include John Camoriano, Carrie Langstraat, Jun Yin, Aminah Jatoi, Tri A. Dinh, Mabel Ryder, Crystal Hilger, Matthew Robertson, Gretchen Glaser and Xiaonan Hou and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Erik Asmus

9 papers receiving 178 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Erik Asmus United States 6 100 55 43 41 39 9 179
Talia Mitchell United States 6 25 0.3× 26 0.5× 31 0.7× 43 1.0× 26 0.7× 6 154
Jana Drozenová Czechia 8 66 0.7× 83 1.5× 45 1.0× 34 0.8× 49 1.3× 29 202
Thais Maloberti Italy 6 62 0.6× 33 0.6× 18 0.4× 31 0.8× 54 1.4× 40 164
Ornella Nicoletto Italy 9 69 0.7× 11 0.2× 43 1.0× 41 1.0× 78 2.0× 15 180
Tatjana Božanović Serbia 9 63 0.6× 6 0.1× 31 0.7× 14 0.3× 70 1.8× 19 182
Petra Jankowska United Kingdom 4 34 0.3× 32 0.6× 21 0.5× 24 0.6× 35 0.9× 6 141
Uriel Bohn Spain 9 144 1.4× 48 0.9× 19 0.4× 85 2.1× 33 0.8× 16 253
Jarosław Dębniak Poland 10 78 0.8× 9 0.2× 112 2.6× 23 0.6× 133 3.4× 25 284
Ebru İnci Çoşkun Türkiye 9 11 0.1× 20 0.4× 16 0.4× 15 0.4× 131 3.4× 22 236
Naïri Tchrakian Canada 7 50 0.5× 5 0.1× 20 0.5× 27 0.7× 36 0.9× 12 145

Countries citing papers authored by Erik Asmus

Since Specialization
Citations

This map shows the geographic impact of Erik Asmus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik Asmus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik Asmus more than expected).

Fields of papers citing papers by Erik Asmus

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik Asmus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik Asmus. The network helps show where Erik Asmus may publish in the future.

Co-authorship network of co-authors of Erik Asmus

This figure shows the co-authorship network connecting the top 25 collaborators of Erik Asmus. A scholar is included among the top collaborators of Erik Asmus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik Asmus. Erik Asmus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
2.
Fuentes, Harry E, Jun Yin, Erik Asmus, et al.. (2022). Lenvatinib as a Therapeutic Option in Unresectable Metastatic Pheochromocytoma and Paragangliomas. Journal of the Endocrine Society. 6(5). bvac044–bvac044. 11 indexed citations
3.
Kumar, Shaji, Melissa Alsina, Betsy LaPlant, et al.. (2022). Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial. Blood. 140(Supplement 1). 1830–1832. 17 indexed citations
4.
Magbanua, Mark Jesus M., Oleksandr Savenkov, Erik Asmus, et al.. (2020). Clinical Significance of Circulating Tumor Cells in Hormone Receptor–positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab. Clinical Cancer Research. 26(18). 4911–4920. 19 indexed citations
5.
Colón‐Otero, Gerardo, Valentina Zanfagnin, Xiaonan Hou, et al.. (2020). Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers. ESMO Open. 5(5). e000926–e000926. 61 indexed citations
6.
Liu, Minetta C., David W. Hillman, Alan P. Lyss, et al.. (2020). Randomized phase III trial of eribulin (E) versus standard weekly paclitaxel (P) as first- or second-line therapy for locally recurrent or metastatic breast cancer (MBC).. Journal of Clinical Oncology. 38(15_suppl). 1016–1016. 5 indexed citations
7.
Chintakuntlawar, Ashish V., Jun Yin, Robert L. Foote, et al.. (2019). A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer. Thyroid. 29(11). 1615–1622. 57 indexed citations
8.
Hayman, Suzanne R., Betsy LaPlant, Francis K. Buadi, et al.. (2019). Phase 1/2 Trial of Carfilzomib and Melphalan Conditioning for Autologous Stem Cell Transplantation for Multiple Myeloma (CARAMEL). Biology of Blood and Marrow Transplantation. 25(3). S30–S30. 1 indexed citations
9.
Colón‐Otero, Gerardo, S. John Weroha, Valentina Zanfagnin, et al.. (2019). Results of a phase 2 trial of ribociclib and letrozole in patients with either relapsed estrogen receptor (ER)-positive ovarian cancers or relapsed ER-positive endometrial cancers.. Journal of Clinical Oncology. 37(15_suppl). 5510–5510. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Talia Mitchell Breakdown of academic impact, for papers by Jana Drozenová Breakdown of academic impact, for papers by Thais Maloberti Breakdown of academic impact, for papers by Ornella Nicoletto Breakdown of academic impact, for papers by Tatjana Božanović Breakdown of academic impact, for papers by Petra Jankowska Breakdown of academic impact, for papers by Uriel Bohn Breakdown of academic impact, for papers by Jarosław Dębniak Breakdown of academic impact, for papers by Ebru İnci Çoşkun Breakdown of academic impact, for papers by Naïri Tchrakian
Rankless by CCL
2026